# A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

> **NCT03781167** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 244 (actual)

## Conditions studied

- Parkinson's Disease (PD)

## Interventions

- **DRUG:** ABBV-951

## Key facts

- **NCT ID:** NCT03781167
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-29
- **Primary completion:** 2022-08-17
- **Final completion:** 2022-08-17
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03781167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03781167, "A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03781167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*